KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Total Liabilities (2016 - 2025)

Novavax (NVAX) has 16 years of Total Liabilities data on record, last reported at $1.3 billion in Q4 2025.

  • For Q4 2025, Total Liabilities fell 40.29% year-over-year to $1.3 billion; the TTM value through Dec 2025 reached $1.3 billion, down 40.29%, while the annual FY2025 figure was $1.3 billion, 40.29% down from the prior year.
  • Total Liabilities reached $1.3 billion in Q4 2025 per NVAX's latest filing, down from $1.3 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $3.0 billion in Q2 2022 and bottomed at $1.3 billion in Q2 2025.
  • Average Total Liabilities over 5 years is $2.2 billion, with a median of $2.2 billion recorded in 2024.
  • Peak YoY movement for Total Liabilities: surged 345.76% in 2021, then tumbled 42.28% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $2.9 billion in 2021, then decreased by 1.22% to $2.9 billion in 2022, then fell by 13.08% to $2.5 billion in 2023, then dropped by 13.13% to $2.2 billion in 2024, then crashed by 40.29% to $1.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $1.3 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.3 billion in Q2 2025.